Biohaven forms license pact with Ono for IgG degraders
Ono Pharmaceuticals obtained an exclusive global license to develop and commercialize Biohaven's IgG degraders, including BHV-1300, BHV-1310 and BHV-1320, with the agreement signed on October 8, 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed